This is the authors' abstract. We don't add key points for this paper.
Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: